Early stage biopharmaceutical concern Autolus Therapeutics plc has fallen over 60% in the past year.
Part of that downdraft was attributable to a post-IPO correction typical of most biotech names, especially in the hot T cell therapy market.
The other component of the selloff was the massive redemptions at one of its largest shareholders, Woodford.
With the redemption overhang now gone and many early shots on goal, Autolus merited a deeper dive.
Why is there never a headline that says "Government program ends as its intended goal has been achieved"?"- Oleg Atbashian
Today, we look at an oncology concern from across the pond. The company recently